FI67856C - Foerfarande foer framstaellning av ett antibakteriellt silversalt av fosfanilsyra - Google Patents
Foerfarande foer framstaellning av ett antibakteriellt silversalt av fosfanilsyra Download PDFInfo
- Publication number
- FI67856C FI67856C FI793851A FI793851A FI67856C FI 67856 C FI67856 C FI 67856C FI 793851 A FI793851 A FI 793851A FI 793851 A FI793851 A FI 793851A FI 67856 C FI67856 C FI 67856C
- Authority
- FI
- Finland
- Prior art keywords
- silver
- phosphanilic acid
- mixed
- acid
- phosphanilic
- Prior art date
Links
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 title claims description 6
- OAOBMEMWHJWPNA-UHFFFAOYSA-N (4-aminophenyl)phosphonic acid Chemical compound NC1=CC=C(P(O)(O)=O)C=C1 OAOBMEMWHJWPNA-UHFFFAOYSA-N 0.000 claims description 25
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 12
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000000908 ammonium hydroxide Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 description 10
- 239000002674 ointment Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000588653 Neisseria Species 0.000 description 5
- 241000589516 Pseudomonas Species 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229960003600 silver sulfadiazine Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 241000606790 Haemophilus Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003378 silver Chemical class 0.000 description 3
- 241000894007 species Species 0.000 description 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000588697 Enterobacter cloacae Species 0.000 description 2
- 241000219470 Mirabilis Species 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 241001312524 Streptococcus viridans Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000038458 Nepenthes mirabilis Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 244000110797 Polygonum persicaria Species 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 102000013537 Thymidine Phosphorylase Human genes 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- XYCMAGGWUVMJHM-UHFFFAOYSA-L disilver;hydrogen phosphate Chemical compound [Ag+].[Ag+].OP([O-])([O-])=O XYCMAGGWUVMJHM-UHFFFAOYSA-L 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940099261 silvadene Drugs 0.000 description 1
- BSWGGJHLVUUXTL-UHFFFAOYSA-N silver zinc Chemical compound [Zn].[Ag] BSWGGJHLVUUXTL-UHFFFAOYSA-N 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3834—Aromatic acids (P-C aromatic linkage)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96831578 | 1978-12-11 | ||
| US05/968,315 US4177199A (en) | 1978-12-11 | 1978-12-11 | Silver salts of phosphanilic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI793851A7 FI793851A7 (fi) | 1980-06-12 |
| FI67856B FI67856B (fi) | 1985-02-28 |
| FI67856C true FI67856C (fi) | 1985-06-10 |
Family
ID=25514056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI793851A FI67856C (fi) | 1978-12-11 | 1979-12-10 | Foerfarande foer framstaellning av ett antibakteriellt silversalt av fosfanilsyra |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4177199A (en, 2012) |
| JP (1) | JPS5585596A (en, 2012) |
| KR (1) | KR830001662B1 (en, 2012) |
| AU (1) | AU524960B2 (en, 2012) |
| CA (1) | CA1192573A (en, 2012) |
| CH (1) | CH645649A5 (en, 2012) |
| DE (1) | DE2949733A1 (en, 2012) |
| DK (1) | DK522979A (en, 2012) |
| FI (1) | FI67856C (en, 2012) |
| FR (1) | FR2444045A1 (en, 2012) |
| GB (1) | GB2036748B (en, 2012) |
| GR (1) | GR74050B (en, 2012) |
| IE (1) | IE49230B1 (en, 2012) |
| IT (1) | IT1164775B (en, 2012) |
| LU (1) | LU81968A1 (en, 2012) |
| NL (1) | NL7908886A (en, 2012) |
| SE (1) | SE444686B (en, 2012) |
| YU (1) | YU43461B (en, 2012) |
| ZA (1) | ZA796640B (en, 2012) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1004467A3 (nl) * | 1990-06-18 | 1992-11-24 | Sollie Philippe | Stikstof- en zilverhoudend derivaat. |
| US6555333B1 (en) * | 2002-05-14 | 2003-04-29 | Pml Microbiologicals, Inc. | Broad spectrum fastidious organism culture medium |
| US20100015252A1 (en) * | 2008-07-15 | 2010-01-21 | Basf Catalysts Llc | Tooth Polishing Compositions and Methods of Tooth Polishing Without Mechanical Abrasion |
| BRPI0916421A2 (pt) * | 2008-07-15 | 2017-08-29 | Basf Corp | Composição oxidante, e, composição fluida |
| US8311625B2 (en) | 2009-02-04 | 2012-11-13 | Basf Corporation | Chlorine dioxide treatment for biological tissue |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2328358A (en) * | 1941-01-23 | 1943-08-31 | Du Pont | Organic compound and process for preparing the same |
| US3694447A (en) * | 1970-03-10 | 1972-09-26 | Smith Kline French Lab | Complexes of phosphanilic acid and 9-amino-3-nitroacridine |
| GB1346544A (en) * | 1971-06-01 | 1974-02-13 | Univ Washington | Silver allantoinate-containing compositions |
| US3856805A (en) * | 1971-06-16 | 1974-12-24 | Univ Washington | Silver zinc allantoin complex |
-
1978
- 1978-12-11 US US05/968,315 patent/US4177199A/en not_active Expired - Lifetime
-
1979
- 1979-10-10 YU YU2457/79A patent/YU43461B/xx unknown
- 1979-11-06 CA CA000339237A patent/CA1192573A/en not_active Expired
- 1979-12-06 FR FR7929992A patent/FR2444045A1/fr active Granted
- 1979-12-07 DK DK522979A patent/DK522979A/da not_active Application Discontinuation
- 1979-12-07 ZA ZA00796640A patent/ZA796640B/xx unknown
- 1979-12-08 KR KR1019790004339A patent/KR830001662B1/ko not_active Expired
- 1979-12-10 CH CH1094579A patent/CH645649A5/fr not_active IP Right Cessation
- 1979-12-10 LU LU81968A patent/LU81968A1/fr unknown
- 1979-12-10 GB GB7942466A patent/GB2036748B/en not_active Expired
- 1979-12-10 IE IE2381/79A patent/IE49230B1/en unknown
- 1979-12-10 IT IT51033/79A patent/IT1164775B/it active
- 1979-12-10 JP JP15931479A patent/JPS5585596A/ja active Granted
- 1979-12-10 AU AU53657/79A patent/AU524960B2/en not_active Ceased
- 1979-12-10 FI FI793851A patent/FI67856C/fi not_active IP Right Cessation
- 1979-12-10 SE SE7910160A patent/SE444686B/sv unknown
- 1979-12-10 NL NL7908886A patent/NL7908886A/nl not_active Application Discontinuation
- 1979-12-11 GR GR60721A patent/GR74050B/el unknown
- 1979-12-11 DE DE19792949733 patent/DE2949733A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB2036748A (en) | 1980-07-02 |
| IE49230B1 (en) | 1985-09-04 |
| IT7951033A0 (it) | 1979-12-10 |
| AU524960B2 (en) | 1982-10-14 |
| CH645649A5 (fr) | 1984-10-15 |
| CA1192573A (en) | 1985-08-27 |
| FR2444045B1 (en, 2012) | 1984-09-14 |
| NL7908886A (nl) | 1980-06-13 |
| DK522979A (da) | 1980-06-12 |
| KR830001662B1 (ko) | 1983-08-23 |
| AU5365779A (en) | 1980-06-19 |
| SE7910160L (sv) | 1980-06-12 |
| KR830000906A (ko) | 1983-04-28 |
| US4177199A (en) | 1979-12-04 |
| GB2036748B (en) | 1983-07-20 |
| FI793851A7 (fi) | 1980-06-12 |
| FI67856B (fi) | 1985-02-28 |
| FR2444045A1 (fr) | 1980-07-11 |
| GR74050B (en, 2012) | 1984-06-06 |
| JPS5585596A (en) | 1980-06-27 |
| YU43461B (en) | 1989-08-31 |
| IT1164775B (it) | 1987-04-15 |
| JPS6254313B2 (en, 2012) | 1987-11-13 |
| LU81968A1 (fr) | 1980-07-01 |
| DE2949733A1 (de) | 1980-06-19 |
| SE444686B (sv) | 1986-04-28 |
| YU245779A (en) | 1983-02-28 |
| IE792381L (en) | 1980-06-11 |
| ZA796640B (en) | 1981-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR930002509B1 (ko) | 결정성 칼슘 슈도모네이트 제법 | |
| EP0163550A2 (en) | Mitomycin derivatives, preparation thereof and pharmaceutical compositions containing them | |
| JPH02288888A (ja) | テイコマイシンａ↓２純粋単―ファクタ―４ | |
| HU181497B (en) | Process for preparing crystalline sodium salt of oximino-7-amino-thiazolyl-acetamido-3-acetoxymethyl-cef-3-em-4-carboxylic acid | |
| FI67856C (fi) | Foerfarande foer framstaellning av ett antibakteriellt silversalt av fosfanilsyra | |
| CA1108631A (en) | Bis-(2-ammonium-2-hydroxymethyl-1,3-propanediol) (2r- cis)-(3-methyloxiranyl)-phosphonate | |
| CA1095931A (en) | Process for the preparation of p-aminomethyl-benzene- sulfonamide derivatives | |
| KR20170032348A (ko) | 저 치환된 폴리믹신 및 이의 조성물 | |
| IL46650A (en) | Antibiotic compositions containing sodium 7-(d-2 formyloxy-2-phenyl-acetamido)-3-(1 methyl-1h-tetrazole-5-ylthiomethyl)-3-cephem-4 carboxylate | |
| JPH0631301B2 (ja) | 抗細菌性９−デオキソ―９ａ―アリルおよびプロパルギル―９ａ―アザ―９ａ―ホモエリスロマイシンＡ誘導体 | |
| Fukase et al. | C-2801X, a new cephamycin-type antibiotic II. Isolation and characterization | |
| JPH0317840B2 (en, 2012) | ||
| CA1192491A (en) | Silver salts of phosphanilic acid | |
| Pierson et al. | In-vitro activity of Sch 29482, MK 0787, ceftriaxone and seven other antimicrobials against 840 separate clinical isolates | |
| RU2003655C1 (ru) | Метиловый эфир 4-оксо-4-фенил-2-(9-флуорениленгидразино)-2-бутеновой кислоты, ингибирующий рост грамположительной микрофлоры | |
| KR20060002915A (ko) | 결정성 ｎ-포르밀 히드록실아민 화합물 | |
| Lowbury | Recent Developments in Burn Management and Research: Prevention and Treatment of Sepsis in Burns | |
| US4327105A (en) | Amino-penicillin derivative, and therapeutic composition containing the same | |
| Wright et al. | Comparative in vitro activity of lomefloxacin (SC 47111 or NY-198) against fresh clinical bacterial isolates | |
| SU782317A1 (ru) | 1,2-Дибензоилпирувоилгидразин,обладающий антимикробной активностью | |
| EP0369503B1 (en) | Method for the control of pneumocystis carinii | |
| JPS6234038B2 (en, 2012) | ||
| SU1100866A1 (ru) | 2-Метоксикарбонилбромметилен-5-п-толил-2,3-дигидрофуран-3-он, про вл ющий антимикробную активность | |
| US4695565A (en) | Antibacterial 7β-heterocyclic-cephem | |
| KR100226273B1 (ko) | 신규 세팔로스포린계 수용성 유도체 및 그의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: BRISTOL-MYERS CO |